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Mangrove and its derived actinobacteria
strains are well known for producing
novel secondary metabolites and pos-
sessing highly effective bioactive com-
pounds, possibly due to biochemical
adaptation to the special intertidal eco-
system (Li et al., 2013). Streptomyces
xiamenensis was identified as a novel
species of actinobacteria from mangrove
sediments (Xu et al., 2009). In this study,
a series of benzopyran derivatives,
named xiamenmycin A-D (1-3), were
discovered from S. xiamenensis as
potential lead compounds against
excessive fibrotic diseases (Figure 1)
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Figure 1. Xiamenmycin and its derivatives are novel drug candidates for suppressing hypertrophic scars. Xiamenmycin was isolated from mangrove-derived
S. xiamenensis. The structure shows benzopyran skeleton, isoprene side chain, and amino-acid moiety. Xiamenmycin A possessed anti-hypertrophic scars
bioactivity. Further phytochemical study was carried on and more novel derivatives were found for SAR investigation.
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(Xu et al., 2012; You et al., 2013).
The promising anti-fibrotic activities of
xiamenmycins have triggered efforts
to determine the structure, increase
structural diversity, and find the gene
cluster responsible for biosynthesis.
Structurally, the absolute configuration
of xiamenmycin A was determined by
extensive spectroscopic data analyses,
Mosher’s method, Marfey’s reagent, and
quantum mechanical calculations (Xu
et al., 2012). Genetically, the introduc-
tion of spontaneous rifampicin resistance
combined with streptomycin resistance by
introducing a mutated rpsL gene into S.
xiamenensis was performed to increase
the production of its secondary meta-
bolites and two more new benzopyran
derivatives were isolated (You et al.,
2013). The biosynthetic pathway was
elucidated and all the genes in the path-
way were genetically and biochemically
characterized.
Pharmacologically, we found that xia-
menmycin A could significantly inhibit
cell proliferation and activation of pri-
mary human dermal fibroblast (HDF),
and reduced the contractile ability of
HDF, indicating that the compound
might have anti-fibrotic effect (Liu
et al., 2013). By using a mechanical
stretch-induced mouse hypertrophic
scar model, we found that xiamen-
mycin A significantly attenuated
hypertrophic scar formation and had
no significant toxic effect on mice.
Furthermore, the compound could sup-
press local inflammation by reducing
CD4þ lymphocyte and monocyte/
macrophage retention in fibrotic foci
and blocked fibroblast adhesion with
monocytes. Both in vivo and in vitro
studies found that the compound
inhibited the mechanical stress-induced
profibrotic effects by suppressing pro-
liferation, activation, and fibroblast
contraction, and inactivating FAK, p38,
and Rho guanosine triphosphatase
signaling.
From the primary analysis of the
structure–activity relationship (SAR)
between xiamenmycins, we found that
compounds 1–3 shared the same ben-
zopyran skeleton and isoprene side
chain. The only difference in the struc-
tures is in the amino-acid moiety (on
position 10). Xiamenmycin C (2) was
found to exhibit inhibitory effects on
the cell proliferation of human lung
fibroblasts (WI26) using lower doses
compared with xiamenmycin. It seems
that the benzopyran skeleton is crucial
for the anti-fibrotic activity. Xiamenmy-
cin D (3) showed anti-fibrotic activity
similar to xiamenmycin. It indicated that
the methylation at C60 position may not
effect the bioactivity. As a type of
potential anti-fibrotic drug, more diverse
benzopyran structures are needed for
the investigation of the SAR.
Taken together, our data suggest that
xiamenmycin A could simultaneously
suppress both the inflammatory and
mechanical stress responses, which are
the two pivotal pathological processes
in hypertrophic scar formation, thus
suggesting that xiamenmycins can serve
as a potential agent for treating hyper-
trophic scar formation and other fibrotic
disorders. Xiamenmycins are structu-
rally, biosynthetically, and pharmacolo-
gically remarkable natural products for
new anti-fibrotic drug discovery.
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